BTMD logo

BIOTE CORP -A

BTMDNASDAQ
๐Ÿ† #4224 by market capEarnings Mar 9 ยท PostUS Equity
$0.82โ–ผ $0.03 (โˆ’2.98%)
Market closed ยท at close
๐Ÿ””
Track BTMD
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ผ 3.0%
7dโ–ผ 23.5%
14dโ–ผ 21.6%
30dโ–ผ 23.5%
ytdโ–ผ 68.5%
1yโ–ผ 68.8%
๐ŸฆMarket Cap
$29M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
-7.8%
Declining
๐Ÿ“ŠGross Margin
68.6%
High
๐Ÿ’ตFCF Margin
14.4%
Healthy
โš–๏ธP/S Ratio
0.2x
Cheap
Otter Score
โ€”
Insufficient data

Trading Snapshot

Day Range
$0.82 โ€“ $0.82
52-Week Range
$0.81 โ€“ $2.90
Volume (shares)
257
Avg Volume (shares)
โ€”
Shares Outstanding
35.9M
Next Earnings
2027-03-09

Fundamentals Snapshot

Annual Revenue
$192M
Last Q Revenue
$43M
P/E Ratio
7.7
P/S Ratio
0.2x
EPS (TTM)
$0.11
Dividend Yield
โ€”
BTMD logo

BIOTE CORP -A

BTMD
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About BIOTE CORP -A

Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization. The company provides a comprehensive system for its Biote-certified healthcare professionals, enabling them to correct imbalances in patients' hormone, vitamin, and mineral levels. This includes authorizing the prescription of bioidentical hormone treatments and suggesting suitable dietary supplements. Furthermore, Biote offers its own line of branded nutritional supplements and supplies sterile kits for inserting hormone pellets for both male and female individuals. Founded in 2011, Biote Corp. is based in Irvine, Texas.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100

Analyst Ratings

โ“˜
Consensus
Buy
11 analysts
Strong Buy3
Buy6
Hold2
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

News unavailable.